ATE195423T1 - L-2',3'-dideoxy-nukleosidanaloga als anti- hepatitis b-(hbv) und anti-hiv-wirkstoffe - Google Patents

L-2',3'-dideoxy-nukleosidanaloga als anti- hepatitis b-(hbv) und anti-hiv-wirkstoffe

Info

Publication number
ATE195423T1
ATE195423T1 AT94919207T AT94919207T ATE195423T1 AT E195423 T1 ATE195423 T1 AT E195423T1 AT 94919207 T AT94919207 T AT 94919207T AT 94919207 T AT94919207 T AT 94919207T AT E195423 T1 ATE195423 T1 AT E195423T1
Authority
AT
Austria
Prior art keywords
hbv
dideoxy
hiv
present
hepatitis
Prior art date
Application number
AT94919207T
Other languages
English (en)
Inventor
Tai-Shun Lin
Yung-Chi Cheng
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of ATE195423T1 publication Critical patent/ATE195423T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT94919207T 1993-05-25 1994-05-23 L-2',3'-dideoxy-nukleosidanaloga als anti- hepatitis b-(hbv) und anti-hiv-wirkstoffe ATE195423T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6729993A 1993-05-25 1993-05-25
US08/098,650 US5627160A (en) 1993-05-25 1993-07-28 L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
PCT/US1994/005790 WO1994027616A1 (en) 1993-05-25 1994-05-23 L-2',3'-dideoxy nucleoside analogs as anti-hepatitis b (hbv) and anti-hiv agents

Publications (1)

Publication Number Publication Date
ATE195423T1 true ATE195423T1 (de) 2000-09-15

Family

ID=26747712

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94919207T ATE195423T1 (de) 1993-05-25 1994-05-23 L-2',3'-dideoxy-nukleosidanaloga als anti- hepatitis b-(hbv) und anti-hiv-wirkstoffe

Country Status (14)

Country Link
US (1) US5627160A (de)
EP (1) EP0707481B1 (de)
JP (2) JPH08510747A (de)
KR (1) KR100279953B1 (de)
CN (1) CN1076021C (de)
AT (1) ATE195423T1 (de)
CA (1) CA2163520C (de)
DE (1) DE69425574T2 (de)
DK (1) DK0707481T3 (de)
ES (1) ES2150993T3 (de)
GR (1) GR3034379T3 (de)
HK (1) HK1013257A1 (de)
PT (1) PT707481E (de)
WO (1) WO1994027616A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5512431A (en) * 1994-06-29 1996-04-30 Darwin Molecular Corporation Methods of screening for nucleoside analogs that are incorporated by HIV reverse transcriptase and cause incorrect base pairing
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
WO1996028162A1 (en) * 1995-03-14 1996-09-19 University Of Medicine & Dentistry Of New Jersey New drug combination for the treatment of viral diseases
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
EP0831852B1 (de) * 1995-06-07 2006-11-29 Emory University Nucleoside mit anti-hepatitis b virus wirksamkeit
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
CN1233254A (zh) * 1996-10-16 1999-10-27 Icn药品公司 嘌呤l-核苷、其类似物及其用途
EP1302474A1 (de) * 1996-10-16 2003-04-16 Ribapharm, Inc. Monzyklische L-Nukleoside, deren Analoga und Verwendung
PT1027359E (pt) * 1996-10-16 2003-09-30 Ribapharm Inc L-nucleosideos monociclicos analogos e suas utilizacoes
US6090602A (en) * 1998-02-18 2000-07-18 Promelas Research Corporation Levo-monosaccharide in a nucleoside analog for use as an anti-retroviral agent
CA2340156C (en) * 1998-08-10 2007-10-23 Novirio Pharmaceuticals Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US6525191B1 (en) * 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
WO2002074910A2 (en) 2001-03-15 2002-09-26 Trustees Of Boston College, The Selective anti-viral nucleoside chain terminators
CA2481572A1 (en) * 2002-04-12 2003-10-23 Achillion Pharmaceuticals, Inc. Method for synthesizing .beta.-l-5-fluoro-2',3'-dideoxy-2',3'-didehydrocytidine(.beta.-l-fd4c)
US20040067877A1 (en) * 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
WO2005026186A1 (de) * 2003-09-12 2005-03-24 Max-Delbrück-Centrum für Molekulare Medizin Β-l-nucleoside und ihre verwendung als pharmazeutische mittel zur behandlung viraler erkrankungen
US20060084628A1 (en) 2004-10-19 2006-04-20 Achillion Pharmaceuticals Combination therapy for treating viral infections
GB0513835D0 (en) * 2005-07-07 2005-08-10 Medivir Ab HIV inhibitors
EP2514750B1 (de) 2007-06-18 2013-11-20 Sunshine Lake Pharma Co., Ltd Bromphenylsubstituierte Thiazolydihydropyrimidine
US8816074B2 (en) * 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
EP2513131A4 (de) * 2009-12-17 2013-10-16 Medivir Ab Neue 3´-desoxy-3´-methyliden-l-nukleoside
CN102234280B (zh) * 2010-04-26 2014-01-08 北京大学 D,l-鸟嘌呤核苷类似物及其制备方法和应用
WO2018092728A1 (ja) 2016-11-16 2018-05-24 国立研究開発法人国立国際医療研究センター 抗ウイルス活性等の生理活性を有するヌクレオシド誘導体
KR102077833B1 (ko) 2018-12-10 2020-02-14 류형준 기능성 식품조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
AU591125B2 (en) * 1985-05-15 1989-11-30 Wellcome Foundation Limited, The Therapeutic nucleosides
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
WO1987001284A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
SE8602981D0 (sv) * 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
US4788181A (en) * 1986-09-29 1988-11-29 The United States Of America As Represented By The Department Of Health And Human Services 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity
EP0285884A3 (de) * 1987-03-20 1990-07-04 Bristol-Myers Squibb Company Verfahren zur Herstellung von 2',3'-Dideoxynucleoside
JPH01100191A (ja) * 1987-10-13 1989-04-18 Sanyo Kokusaku Pulp Co Ltd 2′,3′−ジデオキシシチジン類の製造方法
SE8704298D0 (sv) * 1987-11-03 1987-11-03 Astra Ab Compounds for use in therapy
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
JPH07103149B2 (ja) * 1987-11-30 1995-11-08 ヤマサ醤油株式会社 シトシン誘導体の製造法
JPH02152976A (ja) * 1988-05-06 1990-06-12 Bristol Myers Co 2´,3´―ジデヒドロ―2´,3´―ジデオキシヌクレオシドのプロドラッグ
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
JPH0269476A (ja) * 1988-09-06 1990-03-08 Kohjin Co Ltd ピリミジン誘導体の製法
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
US5128458A (en) * 1990-04-20 1992-07-07 Southern Research Institute 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
NZ250842A (en) * 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
CA2135498A1 (en) * 1992-05-13 1993-11-25 Leonid Beigelman Synthesis of nucleotide monomers
DE4224737A1 (de) * 1992-07-27 1994-02-03 Herbert Prof Dr Schott Neue Cytosinnucleosidanaloga, Verfahren zu ihrer Herstellung und ihre Verwendung
HU214980B (hu) * 1992-09-01 1998-08-28 Eli Lilly And Co. Eljárás nukleozidok anomerizálására
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues

Also Published As

Publication number Publication date
DE69425574D1 (en) 2000-09-21
US5627160A (en) 1997-05-06
CN1100303A (zh) 1995-03-22
EP0707481B1 (de) 2000-08-16
CA2163520C (en) 2006-01-10
EP0707481A1 (de) 1996-04-24
JP2004244422A (ja) 2004-09-02
AU693795B2 (en) 1998-07-09
ES2150993T3 (es) 2000-12-16
PT707481E (pt) 2001-02-28
JPH08510747A (ja) 1996-11-12
GR3034379T3 (en) 2000-12-29
WO1994027616A1 (en) 1994-12-08
CA2163520A1 (en) 1994-12-08
AU7043094A (en) 1994-12-20
KR100279953B1 (ko) 2001-02-01
DE69425574T2 (de) 2001-01-04
EP0707481A4 (de) 1996-05-29
DK0707481T3 (da) 2000-10-30
HK1013257A1 (en) 1999-10-22
CN1076021C (zh) 2001-12-12

Similar Documents

Publication Publication Date Title
ATE195423T1 (de) L-2',3'-dideoxy-nukleosidanaloga als anti- hepatitis b-(hbv) und anti-hiv-wirkstoffe
TW374087B (en) L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
ES2022883B3 (es) Una composicion desodorante y uso de ella
EP0287313A3 (en) Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus
CO4750758A1 (es) Compuestos de 5-amino-4-etilsulfinil-1-arilpirazol, composiciones que los contienen y procedimiento para su preparacion
BR9815166A (pt) "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral"
AU4408597A (en) Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
DE69526353D1 (de) Immunologische aktivität der rhamnolipide
KR910000734A (ko) 네플라노신 유도체
ES8605538A1 (es) Procedimiento para la preparacion de nonapeptidos y dodecapeptidos
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
WO2002059123A3 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
ATE63317T1 (de) Teilweise modifizierte analogen von retroinverso neurotensinen.
FR2591890B1 (fr) Composition a usage therapeutique comprenant des composes organo-silicies
SE9701912D0 (sv) Pharmaceutical composition and use thereof
TR200000154T2 (tr) 2,4,4-Trisübstitüe-1,3-Dioksolan mantar önleyiciler.
WO2002055520A3 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
ES2116522T3 (es) Compuestos citotoxicos.
KR900002787A (ko) 인체 후천성 면역부전증후군 바이러스 감염 저해제
TW370531B (en) Novel thymidylate analogs and uses thereof
ES2067140T3 (es) Compuestos fenilester de acido benzoico y composiciones inhibidoras de la elastasa que contienen los mismos.
FR2360312A1 (fr) Compositions antiarthritiques contenant des sels d'or (1+) bis-coordines
KR940703656A (ko) 에이즈 바이러스 감염 저해용 조성물
ES2078139B1 (es) Composiciones antirretrovirales que contienen compuestos iodados.
JPS5677226A (en) Antitumorigenic agent

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee